EMA Authorised: Temomedac (temozolomide) — medac Gesellschaft für klinische Spezialpräparate mbH

View source ↗

Summary

Temomedac (temozolomide) has been authorised in Europe for glioma by medac, with decision date 25/03/2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Temomedac (temozolomide)

Snippet

Status: Authorised. Therapeutic area: Glioma. MAH: medac Gesellschaft für klinische Spezialpräparate mbH. Decision date: 25/03/2022